Home/Pipeline/CSB-001

CSB-001

Limbal Stem Cell Deficiency (LSCD)

UnknownActive

Key Facts

Indication

Limbal Stem Cell Deficiency (LSCD)

Phase

Unknown

Status

Active

Company

Claris Bio

About Claris Bio

Claris Bio is a private, pre-revenue biotechnology company developing a topical biologic therapy for corneal regeneration. The company's lead asset, CSB-001, is a dHGF molecule designed to restore structural and functional integrity in eyes with Limbal Stem Cell Deficiency (LSCD), a severe and sight-threatening condition with limited treatment options. Founded by scientific leaders from Massachusetts Eye and Ear and an experienced ophthalmology CEO, Claris leverages licensed IP from MEEI and a drug substance agreement with Kringle Pharma to advance its program. The company is led by a seasoned team with deep expertise in ophthalmic drug development, clinical strategy, and business development.

View full company profile

Therapeutic Areas

Ophthalmology Corneal Diseases

Other Limbal Stem Cell Deficiency (LSCD) Drugs

Drug	Company	Phase	Status
Holoclar	Holostem Tarapie Avanzate	Approved	Active
KPI-012	Kala Pharmaceuticals	Preclinical	Research/Development